Study Shows Metformin May Reduce Risk of Blood Cancer
A recent study reveals that the diabetes drug metformin may reduce the risk of blood cancer, specifically myeloproliferative neoplasm (MPN). Apart from its primary function, metformin has shown potential in lowering the risk of colorectal, breast, and prostate cancers, as well as cancer-related death. The drug’s benefits also include anti-aging effects, weight loss, improved fertility in individuals with PCOS, and potential cardiovascular health enhancements.
Metformin Shows Promise in Reducing SARS-CoV-2 Levels in Clinical Trial
A recent clinical trial by University of Minnesota researchers found that the common diabetes drug metformin can reduce SARS-CoV-2 levels in the body, potentially lowering the risk of rebound symptoms. The study focused on standard-risk individuals and showed that metformin could decrease viral load, prevent hospitalization or death, and reduce the incidence of long COVID. Early intervention with metformin led to a 3.6-fold reduction in viral load by day 10 and decreased the likelihood of hospitalization or death by 58% within 28 days.
Promising Results in Slowing Parkinson’s Disease Progression
French researchers conduct a one-year study using a GLP-1 receptor agonist, a drug similar to Ozempic, showing promising results in slowing the progression of Parkinson’s disease. This development brings hope to the half a million Americans diagnosed with the illness and offers a glimmer of hope for individuals affected by Parkinson’s disease.
Study Shows SGLT2 Inhibitors May Lower Risk of Kidney Stones in Adults with Type 2 Diabetes
A recent study published in JAMA Internal Medicine found that adults with type 2 diabetes may benefit from lower risk of nephrolithiasis by initiating SGLT2 inhibitors. The research compared the effects of different type 2 diabetes medications on the risk of developing kidney stones and found that SGLT2 inhibitors outperformed other medications in reducing the risk of nephrolithiasis. This finding could have significant implications for the treatment and management of type 2 diabetes, as kidney stones can be a serious complication for individuals with the condition.
SGLT2 Inhibitors May Lower Risk of Kidney Stones in Type 2 Diabetes Patients
Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit…